Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CD | Direct | 3 | ||||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | PIK3CD | Direct | 1 | ||||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | PIK3CD | Direct | 1 | ||||||||
| copanlisib | PIK3CD | Direct | yes | 0 | |||||||
| copanlisib hydrochloride | PIK3CD | Direct | yes | 0 | |||||||
| duvelisib | PIK3CD | Direct | yes | 0 | |||||||
| idelalisib | PIK3CD | Direct | yes | 0 | |||||||
| umbralisib | PIK3CD | Direct | yes | 0 | |||||||
| umbralisib tosylate | PIK3CD | Direct | yes | 0 | |||||||
| sunitinib | CSF1R | SSL via CSF1R | yes | 5 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CSF1R | SSL via CSF1R | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CSK | SSL via CSK | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CA | SSL via PIK3CA | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CG | SSL via PIK3CG | 3 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | IGF1R | SSL via IGF1R | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | CSK | SSL via CSK | 2 | ||||||||
| cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study | IGF1R | SSL via IGF1R | 2 | ||||||||
| cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study | IGF1R | SSL via IGF1R | 2 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CSK | SSL via CSK | 1 | ||||||||
| alpelisib, everolimus, exemestane | PIK3CA | SSL via PIK3CA | 1 | ||||||||
| ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine | DBH | SSL via DBH | 1 | ||||||||
| atorvastatin, temozolomide, radiotherapy | HMGCR | SSL via HMGCR | 1 | ||||||||
| bevacizumab, dasatinib, placebo | CSK | SSL via CSK | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | PIK3CA | SSL via PIK3CA | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | PIK3CG | SSL via PIK3CG | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib | CSF1R | SSL via CSF1R | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | CSF1R | SSL via CSF1R | 1 | ||||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | PIK3CA | SSL via PIK3CA | 1 | ||||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | PIK3CG | SSL via PIK3CG | 1 | ||||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | CSF1R | SSL via CSF1R | 1 | ||||||||
| chemotherapy, disulfiram, gemcitabine hydrochloride, laboratory biomarker analysis | DBH | SSL via DBH | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, mfolfox6 | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, pharmacological study | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | CSK | SSL via CSK | 1 | ||||||||
| disulfiram, copper gluconate, surgery, radiation, temozolomide | DBH | SSL via DBH | 1 | ||||||||
| disulfiram, copper, alkylating agents | DBH | SSL via DBH | 1 | ||||||||
| erdafitinib | CSF1R | SSL via CSF1R | 1 | ||||||||
| gemcitabine, oxaliplatin, imatinib | CSF1R | SSL via CSF1R | 1 | ||||||||
| gemcitabine, sunitinib | CSF1R | SSL via CSF1R | 1 | ||||||||
| imatinib, irinotecan, carboplatin | CSF1R | SSL via CSF1R | 1 | ||||||||
| insulin degludec, insulin glargine | IGF1R | SSL via IGF1R | 1 | ||||||||
| irinotecan, cisplatin, simvastatin | HMGCR | SSL via HMGCR | 1 | ||||||||
| laboratory biomarker analysis, linsitinib, pharmacological study, topotecan hydrochloride | IGF1R | SSL via IGF1R | 1 | ||||||||
| lutetium lu 177 dotatate, capecitabine, temozolomide, quality-of-life assessment, questionnaire administration | SSTR5 | SSL via SSTR5 | 1 | ||||||||
| medical cannabis | HMGCR | SSL via HMGCR | 1 | ||||||||
| nabiximols, temozolomide, nabiximols-matched placebo | HMGCR | SSL via HMGCR | 1 | ||||||||
| oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, ascorbic acid | DBH | SSL via DBH | 1 | ||||||||
| pexidartinib, durvalumab | CSF1R | SSL via CSF1R | 1 | ||||||||
| rosuvastatin | HMGCR | SSL via HMGCR | yes | 1 | |||||||
| ryz101, everolimus, sunitinib, octreotide, lanreotide | CSF1R | SSL via CSF1R | 1 | ||||||||
| ryz101, everolimus, sunitinib, octreotide, lanreotide | SSTR5 | SSL via SSTR5 | 1 | ||||||||
| semaglutide, insulin aspart, insulin glargine u100 | IGF1R | SSL via IGF1R | 1 | ||||||||
| sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide | SSTR5 | SSL via SSTR5 | 1 | ||||||||
| sunitinib, placebo | CSF1R | SSL via CSF1R | 1 | ||||||||
| sunitinib, radiation | CSF1R | SSL via CSF1R | 1 | ||||||||
| sunitinib, sunitinib | CSF1R | SSL via CSF1R | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | DBH | SSL via DBH | 1 | ||||||||
| temozolomide, disulfiram, copper gluconate | DBH | SSL via DBH | 1 | ||||||||
| temozolomide, radiation therapy, ascorbic acid | DBH | SSL via DBH | 1 | ||||||||
| alpelisib | PIK3CA | SSL via PIK3CA | yes | 0 | |||||||
| atorvastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| atorvastatin calcium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| brigatinib | IGF1R | SSL via IGF1R | yes | 0 | |||||||
| cerivastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| cerivastatin sodium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| copanlisib | PIK3CA | SSL via PIK3CA | yes | 0 | |||||||
| copanlisib hydrochloride | PIK3CA | SSL via PIK3CA | yes | 0 | |||||||
| duvelisib | PIK3CG | SSL via PIK3CG | yes | 0 | |||||||
| fluvastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| fluvastatin sodium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| lanreotide | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| lanreotide acetate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| lemborexant | HCRTR1 | SSL via HCRTR1 | yes | 0 | |||||||
| lovastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| mecasermin | IGF1R | SSL via IGF1R | yes | 0 | |||||||
| mecasermin rinfabate | IGF1R | SSL via IGF1R | yes | 0 | |||||||
| octreotide | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| octreotide acetate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| pasireotide | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| pasireotide diaspartate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| pasireotide pamoate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| pazopanib | CSF1R | SSL via CSF1R | yes | 0 | |||||||
| pazopanib hydrochloride | CSF1R | SSL via CSF1R | yes | 0 | |||||||
| pexidartinib | CSF1R | SSL via CSF1R | yes | 0 | |||||||
| pexidartinib hydrochloride | CSF1R | SSL via CSF1R | yes | 0 | |||||||
| pitavastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| pitavastatin calcium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| pitavastatin magnesium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| pitavastatin sodium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| pravastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| pravastatin sodium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| rosuvastatin calcium | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| simvastatin | HMGCR | SSL via HMGCR | yes | 0 | |||||||
| somatropin | IGF1R | SSL via IGF1R | yes | 0 | |||||||
| sunitinib malate | CSF1R | SSL via CSF1R | yes | 0 | |||||||
| suvorexant | HCRTR1 | SSL via HCRTR1 | yes | 0 |